News
6
minutes reading time
Another major investment round for Xeltis: €32 million for the development of restorative cardiovascular devices
Xeltis, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, has raised €32 million in a Series D2 equity fundraise.